World's First! Original Drug from Jinwan Officially Launched

ZHUHAI, China — For parents of newborns in China, respiratory syncytial virus has long been one of the most feared threats of infancy. Now, a homegrown biotech company says it has a weapon that could change that calculus.

Zhuhai Trinomab Pharmaceutical Co., Ltd. announced the commercial launch of its long-acting anti-RSV monoclonal antibody — branded Xinduotuo — from its headquarters in Jinwan District, Zhuhai. The product, known generically as ruiteweibai monoclonal antibody injection, represents what the company calls the world's first long-acting anti-RSV antibody with clinical data demonstrating nine months of protection from a single dose.

The launch fills a gap that has persisted for years in China's pediatric prevention arsenal: until now, the country had no domestically developed preventive antibody specifically targeting RSV in infants.

A First in the Field

RSV is the leading cause of lower respiratory tract infections in infants worldwide, responsible for millions of hospitalizations each year. For decades, the medical community has searched for an effective preventive treatment — particularly one that could protect vulnerable newborns through their most susceptible months.

Trinomab's offering claims to address that need with a single injection providing up to nine months of protection, potentially covering an infant through an entire RSV season. The company developed and manufactured the product entirely in-house, making it a fully domestic innovation.

Filling a Domestic Void

The approval and launch mark a milestone for China's biotech sector, which has been pushing to develop original therapies rather than generic copies. The product is classified as a domestically developed, original-research drug — a designation that signals genuine innovation rather than incremental improvement.

For Trinomab, based in the Pearl River Delta city of Zhuhai, the launch validates years of research investment. The company positioned Xinduotuo as a safe, accessible, and effective "Chinese solution" for infant respiratory health — a framing that underscores both the medical need and the national pride embedded in the achievement.

What Comes Next

The real test will be adoption. Chinese parents, increasingly discerning about pediatric care, will weigh the new option against existing alternatives and watch for real-world effectiveness data. Hospitals and clinics will need to stock and recommend the product. And regulators will monitor post-market safety as the antibody reaches broader use.

But for now, Trinomab has secured a first-mover position in a market with enormous unmet need — and a product that, if it delivers on its promise, could protect millions of China's most vulnerable patients.